AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23474348
Drug: Farletuzumab with
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Farletuzumab with chemotherapy
Trial: 23475281
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m(2)) and carboplatin (AUC = 6 mg/mL·min) followed by maintenance pemetrexed
Trial: 23475406
Drug: Tapentadol prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol prolonged release (PR; 50-250 mg b.i.d.)
Trial: 23477833
Drug: Cixutumumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-positive soft-tissue sarcoma (group A)
Trial: 23477833
Drug: Cixutumumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-positive bone sarcoma (group B)
Trial: 23477833
Drug: Cixutumumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-negative bone and soft-tissue sarcoma (group C)
Trial: 23478952
Drug: Telaprevir (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telaprevir (750 mg every 8 hours for 7 days)
Trial: 23480759
Drug: Intermittent-high dose
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent-high dose oral calcitriol 12 μg/day for 3 days per week for up to 3 months (n=2)
Trial: 23480759
Drug: Chemotherapeutic drugs
RxNorm normalized name: Other chemotherapeutics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapeutic drugs (5-fluorouracil, Mitomycin C, and Leucovorin) for 3 cycles (n=3)
Trial: 23480759
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose calcitriol in combination with chemotherapeutic drugs (n=4)
Trial: 23483536
Drug: Non-ASA NSAIDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-ASA NSAIDs and acetaminophen
Trial: 23483678
Drug: CP-870,893 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-870,893 (0.1 mg/Kg or 0.2 mg/Kg) combined with carboplatin and paclitaxel
Trial: 23483678
Drug: CP-870,893 (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-870,893 (0.2 mg/Kg)
Trial: 23484911
Drug: Oral fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fat load of 700 kilocalories per m² of body surface area at 83% fat after an 8-h fast.
Trial: 23487538
Drug: Vandetanib therapy
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vandetanib therapy
Trial: 23488447
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart 30 (BIAsp 30) therapy
Trial: 23489023
Drug: Vemurafenib (240-360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib (240-360 mg twice a day, escalated to 720 mg twice a day)
Trial: 23489534
Drug: Group III:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group III: High-dose (100 mg) t-PA
Trial: 23489534
Drug: Group IV:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group IV: Half-dose (50 mg) t-PA, slow infusion (6 h) without bolus
Trial: 23489534
Drug: Group V:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group V: Low-dose (25 mg) t-PA, slow infusion (6 h) without bolus
Trial: 23489912
Drug: Sequential finger-thumb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential finger-thumb opposition test
Trial: 23490650
Drug: BMS-690514 (200mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-690514 (200mg daily)
Trial: 23490654
Drug: Sequential arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential arm S treated with 5-fluorouracil and leucovorin (LV5FU2) followed by FOLFOX (LV5FU2+oxaliplatin) and then FOLFIRI (LV5FU2+irinotecan)
Trial: 23490654
Drug: Combination arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination arm C that begins directly with FOLFOX followed by FOLFIRI
Trial: 23490654
Drug: Sequential arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential arm S
Trial: 23490654
Drug: Combination arm
RxNorm normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination arm C
Trial: 23494041
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g of omega-3 fatty acids daily (840 mg eicosapentaenoic acid/2520 mg docosahexaenoic acid) for 6 months
Trial: 23494984
Drug: Darunavir/ritonavir (600/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir (600/100 mg twice daily)
Trial: 23497046
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy for 1 month
Trial: 23497305
Drug: Bevacizumab (Avastin™)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (Avastin™) in combination with XELOX or mFOLFOX6
Trial: 23497305
Drug: Bevacizumab (Avastin™)
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab (Avastin™) in combination with FOLFIRI
Trial: 23497336
Drug: Eltrombopag 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 150 mg daily
Trial: 23497336
Drug: AI chemotherapy
RxNorm normalized name: AI-128
DrugBank: AI-128 (DB05841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI chemotherapy (without eltrombopag)
Trial: 23497349
Drug: Carbon ion
RxNorm normalized name: CARBON ION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon ion therapy (4 × 10 Gy(RBE))
Trial: 23497365
Drug: Weekly docetaxel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy; 30 mg/m² docetaxel on day 1 and 8, 60 mg/m² cisplatin on day 1, and 70 mg/m² S-1 on days 1 to 14, repeated every 21 days.
Trial: 23497558
Drug: Ex vivo
RxNorm normalized name: Allogeneic ex vivo expanded umbilical cord blood cells
DrugBank: Carlecortemcel-L (DB17186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo tacrolimus perfusion at a concentration of 20 ng/ml in 1000 ml Custodiol solution
Trial: 23497667
Drug: Drug-related problems
RxNorm normalized name: Psoriasin Problem Skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-related problems (DRPs) identified in patients presenting with NSC
Trial: 23497667
Drug: Drug-related problems
RxNorm normalized name: Psoriasin Problem Skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-related problems (DRPs)
Trial: 23497667
Drug: Polypharmacy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy and certain drug classes (thiazides, antidepressants, benzodiazepines, anticonvulsants)
Trial: 23497731
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise training (12-week program with a minimum requirement of 17.5 kcal/kg weekly energy expenditure)
Trial: 23500218
Drug: iFRa (iFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iFRa (iFR during adenosine administration)
Trial: 23500322
Drug: Daily monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily monitoring of B-type natriuretic peptide (BNP) levels for 60 days with a finger-stick test.
Trial: 23504398
Drug: Decitabine at
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine at 45 mg/m² IV over 2 hours on day 1 and 15 and panitumumab 6 mg/kg IV over 1 hour on day 8 and 22 every 28 days
Trial: 23504398
Drug: Decitabine and
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine and panitumumab combination
Trial: 23506243
Drug: Raltegravir 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 800 mg qd, Atazanavir 600 mg qd, Lamivudine or Emtricitabine
Trial: 23506243
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg bid, Atazanavir 600 mg qd, Lamivudine or Emtricitabine
Trial: 23511678
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration via nasal cannula at 5 L/min starting 15 minutes after SGB
Trial: 23512637
Drug: EE 30
RxNorm normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 30 μg/LNG 150 μg qd plus empagliflozin 25 mg qd for 7 days (test; period 2)
Trial: 23512637
Drug: EE 30
RxNorm normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 30 μg/LNG 150 μg qd for 14 days (reference; period 1)
Trial: 23512837
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BoNT-A) injection
Trial: 23514360
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily until objective tumor progression, unacceptable toxicity, death, or study discontinuation.
Trial: 23516391
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing of foretinib (240 mg/day for 5 days every 2 weeks)
Trial: 23516391
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of foretinib (80 mg/day)
Trial: 23516391
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing of foretinib (240 mg/day)
Trial: 23516391
Drug: Foretinib treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foretinib treatment
Trial: 23516440
Drug: Telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 40 mg po daily for 24 weeks
Trial: 23517449
Drug: Intradermal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal insulin delivery using a hollow microneedle
Trial: 23517449
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin delivery via insulin pump catheter
Trial: 23518189
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine (initial dose)
Trial: 23519018
Drug: TCR-engineered ACT
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCR-engineered ACT immunotherapy
Trial: 23520311
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg clarithromycin once daily
Trial: 23520311
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg clarithromycin once daily
Trial: 23525441
Drug: Cholesterol absorption
RxNorm normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholesterol absorption markers
Trial: 23525751
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for acute ACL tear, specific intervention details not available.
Trial: 23529375
Drug: Bevacizumab in
RxNorm normalized name: bevacizumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab in combination with radiotherapy and temozolomide
Trial: 23530013
Drug: RYGB surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RYGB surgery with daily matched diet (postsurgery period)
Trial: 23530572
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with 5-FU derivatives (specific regimens not detailed)
Trial: 23530663
Drug: Ganetespib (STA-9090)
RxNorm normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib (STA-9090) administered as a 1 hour IV infusion, once weekly for 3 weeks, followed by a 1-week rest until disease progression or unacceptable toxicity.
Trial: 23530663
Drug: Ganetespib (STA-9090)
RxNorm normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib (STA-9090) at doses escalating from 7 to 259 mg/m(2).
Trial: 23530663
Drug: Ganetespib (STA-9090)
RxNorm normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganetespib (STA-9090) at 200 mg/m(2) given IV at Days 1, 8, and 15 every 4 weeks.
Trial: 23530817
Drug: Morisky Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morisky Medication Adherence Scale (MMAS-4)
Trial: 23530817
Drug: Treatment strategies
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment strategies and associated healthcare costs
Trial: 23531361
Drug: NaHCO3 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 (0.3 g·kg-1 body mass)
Trial: 23531361
Drug: Placebo (0.045
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.045 g·kg-1 body mass NaCl)
Trial: 23535095
Drug: Oral desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desensitization protocol (200 mL)
Trial: 23535095
Drug: Oral desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desensitization protocol
Trial: 23535954
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg + radiotherapy (8 Gy/lesion)
Trial: 23535954
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg - Monotherapy
Trial: 23537041
Drug: Lixisenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide (10 weeks treatment after ischemia-reperfusion)
Trial: 23537041
Drug: Lixisenatide (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide (acute treatment during ischemia-reperfusion)
Trial: 23537041
Drug: Lixisenatide (chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide (chronic treatment)
Trial: 23537121
Drug: Full-mouth scaling
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-mouth scaling and root planing (SRP) and systemic antibiotics
Trial: 23537365
Drug: Low-dose LPS
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose LPS inhalation (2 μg)
Trial: 23537365
Drug: Roflumilast treatment
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast treatment (5 days) before last LPS challenge
Trial: 23537966
Drug: Bendavia at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendavia at 0.05 mg/kg per hour
Trial: 23537966
Drug: Placebo (identically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identically appearing) administered as an intravenous infusion at 60 mL/h
Trial: 23537968
Drug: Pharmacomechanical catheter-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacomechanical catheter-directed thrombolysis (PCDT) + standard therapy
Trial: 23537968
Drug: PCDT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCDT + standard therapy
Trial: 23538866
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy (CT)
Trial: 23539736
Drug: 1-hour OGTT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-hour OGTT glucose of >155 mg/dL
Trial: 23541126
Drug: Venlafaxine ER
RxNorm normalized name: Venlafaxine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine ER (37.5-225 mg/d)
Trial: 23541189
Drug: Lurasidone (40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (40-120 mg/d)
Trial: 23541189
Drug: Olanzapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (15 mg)
Trial: 23542823
Drug: Fecal microbial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fecal microbial transplantation (FMT) - freshly prepared fecal enemas daily for 5 days
Trial: 23543609
Drug: Triazoles (62.7%)
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triazoles (62.7%) and echinocandins (34.2%) were the most commonly used antifungal agents; first-line therapy was typically fluconazole (37.7%).
Trial: 23543609
Drug: First-line antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line antifungal susceptibility.
Trial: 23543609
Drug: Treatment initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment initiated after diagnostic confirmation in 166/268 (61.9%) patients.
Trial: 23543660
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 μg daily for 18 to 24 months)
Trial: 23547218
Drug: Rituximab (RTX)
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (RTX) 2 × 500 mg added to current biologic and nonbiologic DMARD treatment
Trial: 23547558
Drug: OM-174 (600,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OM-174 (600, 800, or 1000 μg/m²) administered as intravenous infusion, twice weekly for a total of 5, 10, or 15 injections.
Trial: 23547655
Drug: Nilotinib (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilotinib (average daily dose of at least 720 mg)
Trial: 23548165
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of [(14)C]pazopanib in suspension (400 mg, 70 µCi)
Trial: 23548165
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 5 mg pazopanib followed by oral administration of 800 mg pazopanib tablet once daily for 26 days
Trial: 23548728
Drug: Antithyroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithyroid therapy (ATT) for 4 months
Trial: 23548879
Drug: Intravenous synthetic
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous synthetic human secretin (sHS) 0.05-0.8 µg/kg for 3 days
Trial: 23549489
Drug: In-hospital management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital management of patients on warfarin undergoing PCI-S
Trial: 23549489
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (warfarin, aspirin, and clopidogrel) prescription at discharge
Trial: 23551108
Drug: High-protein drink
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein drink (325 mL) with ice chips/water PRN
Trial: 23551108
Drug: High-protein drink
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein drink (325 mL)
Trial: 23551593
Drug: everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: everolimus 10 mg orally once daily continuously (one cycle = 4 weeks)
Trial: 23551918
Drug: rFVIIa administration
RxNorm normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa administration for joint bleeds in children
Trial: 23551918
Drug: rFVIIa administration
RxNorm normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rFVIIa administration for joint bleeds in adults
Trial: 23551933
Drug: 2009 trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2009 trivalent inactivated split-virion influenza vaccine (TIV) 0.25 ml (22.5 μg haemagglutinin) or 0.5 ml (45 μg) depending on age and prior vaccination history
Trial: 23552982
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment with grades III and IV toxic effects
Trial: 23552982
Drug: Poor tolerance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poor tolerance of neoadjuvant treatment
Trial: 23553066
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxaliplatin (100 mg/m2), docetaxel (35 mg/m2), and vandetanib (100 mg PO daily)
Trial: 23553066
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxaliplatin (80 mg/m2), docetaxel (30 mg/m2), and vandetanib (100 mg PO daily)
Trial: 23553848
Drug: Cabozantinib 20
RxNorm normalized name: cabozantinib 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 20 mg daily
Trial: 26762579
Drug: Cabozantinib 100
RxNorm normalized name: cabozantinib 100 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 100 mg daily
Trial: 23554030
Drug: Vorinostat (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorinostat (300 mg/m²/day) and Temozolomide (150 mg/m²/day)